首页> 美国卫生研究院文献>Springer Open Choice >Conflicts of interests confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO
【2h】

Conflicts of interests confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO

机译:健康风险评估中的利益冲突保密性和审查制度:除草剂和转基因生物的例子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research into health risks undermines the value and the credibility of science; thus, we republish our paper.
机译:我们已经研究了抗农达转基因玉米(NK603)和整个农达农药制剂在与环境相关的水平(0.1 ppb)起的长期毒性。我们的研究于2012年9月19日首次发表在食品和化学毒理学(FCT)中。第一批批评在一周之内到达,主要是来自没有毒理学经验的植物生物学家。我们回答了所有这些批评。然后,辩论涵盖了科学论据,在利益冲突严重但未披露的作者的不同杂志上出现了一波自发性的批评和潜在的诽谤性评论。与此同时,FCT致孟山都公司的前雇员,因为他给FCT发了一封信来抱怨我们的研究,因此他成为孟山都公司的前雇员,担任其新的生物技术助理编辑。这就是为什么FCT要求对我们的原始数据进行事后分析的原因。 2013年11月19日,总编辑要求撤回我们的研究,同时确认我们的原始数据不正确,不存在任何不当行为,不存在舞弊或故意误解的现象-这是一种异常甚至前所未有的行动在科学出版中。编辑认为,无法得出任何结论,因为我们在2年中每组研究了10只大鼠,因为它们是Sprague Dawley大鼠,并且由于有关癌症的数据尚无定论。然而,在我们提交研究报告时,这是众所周知的。但是,我们的研究从未参加过致癌性研究。我们从未在论文中使用“癌症”一词。本观点是导致这种退缩的辩论的总结,因为它是在世界范围内商业化的产品的科学评估中利益冲突的历史性例子。我们还表明,撤回决定不能基于任何可辨别的科学或道德依据进行合理化。对健康风险进行研究审查会破坏科学的价值和信誉;因此,我们重新发表了论文。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号